Related Experiment Video

Updated: Aug 5, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Fibroblast growth factor receptor signaling in head and neck tumors: molecular pathogenesis and potential therapeutic

Luqin Tang1, Hanqi Xia1, Zhu Zheng1

  • 1Anhui Medical University, Hefei, 230032, China.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|July 31, 2026
PubMed

Insights

Fibroblast Growth Factor Receptor (FGFR) signaling is crucial for cell functions but drives head and neck tumors when abnormal. This review explores FGFR

Area of Science:

  • Oncology
  • Molecular Biology
  • Signaling Pathways

Background:

  • Fibroblast Growth Factor Receptor (FGFR) signaling is vital for normal cellular processes like proliferation and angiogenesis.
  • Aberrant FGFR activation, through genetic alterations or overexpression, significantly contributes to head and neck tumor development and progression.
  • Current targeted therapies using small-molecule FGFR inhibitors show promise but face challenges including tumor heterogeneity and drug resistance.

Purpose of the Study:

  • To systematically review the molecular mechanisms, clinicopathological correlations, and targeted therapy status of the FGFR signaling pathway in various head and neck cancers.
  • To establish a framework connecting genetic alterations, mechanistic regulation, and clinical applications of FGFR signaling in head and neck tumors.
  • To provide a theoretical basis for advancing precision therapy in head and neck oncology.

Main Methods:

  • Systematic literature review of studies on FGFR signaling in head and neck cancers.
  • Analysis of molecular mechanisms, including gene amplification, mutation, fusion, and overexpression.
  • Evaluation of clinicopathological correlations and current targeted therapy approaches.

Main Results:

  • FGFR signaling dysregulation is a key driver in nasopharyngeal carcinoma, salivary gland carcinoma, oral squamous cell carcinoma, thyroid carcinoma, laryngeal carcinoma, and ameloblastoma.
  • Understanding the molecular landscape of FGFR alterations is essential for effective targeted treatment.
  • Challenges in precision therapy include molecular heterogeneity and acquired resistance to inhibitors.

Conclusions:

  • Targeted inhibition of FGFR signaling holds potential for treating specific head and neck tumors.
  • A comprehensive understanding of FGFR alterations and their clinical implications is crucial for developing effective precision therapies.
  • Further research is needed to overcome resistance mechanisms and optimize FGFR-targeted treatments for head and neck cancers.
Keywords:
FGFR signaling pathwayGenetic mutationHead and neck tumorsPathogenesisTargeted therapy

More Related Videos

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...